HighTower Advisors LLC Invests $494,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

HighTower Advisors LLC purchased a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 3rd quarter, Holdings Channel reports. The institutional investor purchased 10,449 shares of the company’s stock, valued at approximately $494,000.

Other large investors have also recently added to or reduced their stakes in the company. Values First Advisors Inc. acquired a new position in shares of Kymera Therapeutics in the 3rd quarter worth approximately $61,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after purchasing an additional 504 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new position in Kymera Therapeutics in the second quarter worth $139,000. Quest Partners LLC increased its stake in Kymera Therapeutics by 1,402.0% during the second quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock valued at $156,000 after purchasing an additional 4,865 shares during the last quarter. Finally, Integrated Advisors Network LLC acquired a new stake in shares of Kymera Therapeutics during the third quarter worth $294,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Stephens assumed coverage on Kymera Therapeutics in a research report on Monday, November 18th. They set an “overweight” rating and a $65.00 price objective for the company. Leerink Partners reiterated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Monday, September 9th. Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Wolfe Research upgraded Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price target for the company in a research report on Monday, August 26th. Finally, BMO Capital Markets assumed coverage on shares of Kymera Therapeutics in a research note on Friday, December 6th. They set a “market perform” rating and a $55.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $53.88.

Kymera Therapeutics Trading Up 3.9 %

Shares of NASDAQ:KYMR opened at $40.66 on Friday. The business’s 50 day moving average is $46.00 and its 200-day moving average is $43.14. The firm has a market capitalization of $2.63 billion, a PE ratio of -17.38 and a beta of 2.16. Kymera Therapeutics, Inc. has a 1-year low of $22.35 and a 1-year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. The firm had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business’s revenue for the quarter was down 20.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.90) EPS. On average, sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.